GCP
IMNM icon

GSA Capital Partners’s Immunome IMNM Stock Holding History

GSA Capital Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242K Buy
+11,051
New +$246K 0.02% 1361
2025
Q4 		– Sell
-66,420
Closed -$778K – 1859
2025
Q3 		$778K Sell
66,420
-9,626
-13% -$95.8K 0.06% 565
2025
Q2 		$707K Buy
+76,046
New +$623K 0.05% 685

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

GSA Capital Partners's IMNM Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Immunome (IMNM) in Q1 2026: 11,051 shares worth $242K. The stake represents 0.02% of the portfolio and ranks #1361 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in IMNM as recently as Q3 2025.

GSA Capital Partners first reported a position in IMNM in Q2 2025 and has held it in 3 quarters since. The position peaked at $778K in Q3 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • GSA Capital Partners held 11,051 shares of Immunome worth $242K as of Q1 2026.
  • Immunome was a new GSA Capital Partners position in Q1 2026.
  • Immunome made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1361 holding.
  • GSA Capital Partners first reported a position in Immunome in Q2 2025 and has held it in 3 quarters since.
  • GSA Capital Partners's Immunome position peaked at $778K in Q3 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.